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A B S T R A C T
Background: Mammography screening programs (MSPs) aim to detect early-stage breast cancers in order
to decrease the incidence of advanced-stage breast cancers and to reduce breast cancer mortality. We
analyzed the time trends of advanced-stage breast cancer incidence rates in the target population before
and after implementation of the MSP in a region of northwestern Germany.
Methods: The MSP in the Münster district started in October 2005. A total of 13,874 women with an
incident invasive breast cancer (BC) was identiﬁed by the population-based epidemiological cancer
registry between 2000 and 2013 in the target group 50–69 years. Multiple imputation methods were
used to replace missing data on tumor stages (10.4%). The incidence rates for early-stage (UICC I) and
advanced-stage (UICC II+) BC were determined, and Poisson regression analyses were performed to
assess trends over time.
Results: The incidence rates for UICC I breast cancers increased during the step-up introduction of the
MSP and remained elevated thereafter. By contrast, after increasing from 2006 to 2008, the incidence
rates of UICC II+ breast cancers decreased to levels below the pre-screening period. Signiﬁcantly
decreasing UICC II+ incidence rates were limited to the age group 55–69 years and reached levels that
were signiﬁcantly lower than incidence rates in the pre-screening period.
Discussion: The incidence rates of advanced-stage breast cancers decreased in the age groups from
55 years to the upper age limit for screening eligibility, but not in the adjacent age groups. The ﬁndings
are consistent with MSP lead time effects and seem to indicate that the MSP lowers advanced-stage
breast cancer rates in the target population.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Invasive breast cancer (ICD 10: C50) is the most common cancer
among women in Germany, with over 70,000 newly diagnosed
cases and over 17,000 deaths in 2010 [1]. Stage of breast cancer at
diagnosis is associated with cancer survival, as patients with early-
stage breast cancers clearly show higher survival rates than those
with advanced-stage breast cancers [2,3]. Therefore, systematic
mammography screening programs (MSP) have been introduced
into routine medical care in many countries [4] with the aim of
detecting breast cancer in its early stages which may be treated
more successfully. As a result, a decrease in the incidence of
advanced-stage breast cancers is assumed to herald a subsequent* Corresponding author at: Institute of Epidemiology and Social Medicine,
University of Münster, Germany.
E-mail address: hense@uni-muenster.de (H.-W. Hense).
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1877-7821/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article unreduction in breast cancer mortality in the group of women eligible
for screening [5].
However, recent studies have produced very controversial
results with regard to the incidence rates of advanced stages of
breast cancer following the implementation of mammography
screening programs; indications of declining late-stage breast
cancers reported by some authors [6–10] were not conﬁrmed by
others [11–14]. In Germany, the MSP started in 2005 and targets
the population of all resident women aged between 50 and
69 years with biennial invitations. The program is organized in line
with the European Guidelines for Quality Assurance in Breast
Cancer Screening and Diagnosis [15].
The aim of this study was to estimate the changes in the
incidence of advanced-stage breast cancers in the target popula-
tion before and after the start of the MSP in a northwestern region
of Germany (the Münster district).der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics.
N (%)
Cases 13.874 (100,0)
Age group
50  54
55  59
60  64
65  69
3.261
3.183
3.706
3.724
(23,5)
(22,9)
(26,7)
(26,8)
T-stage
missing
1
2
3
4
1.178
7.502
4.037
508
649
(8,5)
(54,1)
(29,1)
(3,7)
(4,7)
N-stage
missing
0
1mic
1
2+
1.536
8.021
255
2624
1.438
(11,1)
(57,8)
(1,8)
(18,9)
(10,4)
UICC-stage
missing
I
II+
1.437
5.877
6.560
(10,4)
(42,4)
(47,3)
Morphology
lobular
non-lobular
2.886
10.988
(20,8)
(79,2)
Year of diagnosis
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
806
788
903
869
761
890
1.078
1.185
1.219
1.126
985
1.069
1.045
1.150
(5,8)
(5,7)
(6,5)
(6,3)
(5,5)
(6,4)
(7,8)
(8,5)
(8,8)
(8,1)
(7,1)
(7,7)
(7,5)
(8,3)
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2.1. Data source
The German MSP adheres to the European Guidelines for
Quality Assurance in Breast Cancer Screening and Diagnosis [15].
Accordingly, the target population includes women aged 50–
69 years who are invited biannually. In all study centers, two-view
mammograms were obtained using full-ﬁeld digital mammogra-
phy systems. All mammograms were double-read by certiﬁed
readers, and abnormal ﬁndings detected by one or both readers
resulted in a mandatory consensus meeting with arbitration for
recall invitations.
By the end of 2005, the ﬁrst screening units in Germany started
mammography screening services in the Münster district with a
population of 2.6 million inhabitants. The program was introduced
by opening regional screening units in a step-up manner; the MSP
was fully implemented in the district by the end of 2008 and
continued with a participation rate of around 55% until the end of
the study period in 2013. We obtained information on incident
female breast cancer cases in the years from 2000 to 2013 from the
Epidemiological Cancer Registry of the Münster District, a
subregistry of the state-wide Epidemiological Cancer Registry of
North Rhine–Westphalia; the registry has been collecting data on
cancer incidence with a completeness of more than 90% [1]. This
database, covering a long registration period, was used to assess
changes in breast cancer incidence rates in response to the
implementation of the MSP in NRW.
2.2. Study population
The study population consisted of all women in the Münster
district who were diagnosed with incident breast cancer and who
were in the age range eligible for mammography screening, that is,
aged 50–69 years. To account for delayed effects of screening on
breast cancer incidence due to lead time, we expanded the
population to also include women who were aged 70–79 years. We
further included women aged 45–49 years to address secular
incidence changes that occurred prior to their entering the target
age group. The cancer registry provided tumor-speciﬁc informa-
tion on all newly diagnosed invasive breast cancers (ICD-10: C50)
notiﬁed in the years 2000–2013. In-situ cases (ICD-10: D05) and
death certiﬁcate only (DCO) cases were excluded. The population
numbers per calendar year were obtained from the State Statistical
Bureau (IT NRW).
The information on tumor size and lymph-node involvement (T
and N stage) of each breast cancer case was used to deﬁne a
dichotomized stage according to the UICC classiﬁcation (early
stage: UICC I and advanced stage: UICC II+). UICC I was assigned to
tumors with a T-stage T1 (diameter 20 mm) and with no or
minimal lymph-node involvement (N stage = N0 or N1mic). T
stages T2, T3 or T4 or any number of affected lymph nodes (N
stage = N+ excluding T1N1mic) were coded as UICC II+.
2.3. Statistical methods
2.3.1. Imputation methods
Information on T and/or N stage was missing in 2627 (11.6%) of
all breast cancer cases aged 45–79 years; there were 1437 (10.4%)
missing cases in the MSP target group aged 50–69 years (Table 1).
As informative data for other variables were still available for
patients with a missing UICC classiﬁcation, multiple imputation
methods were used to ﬁll in the missing data. The variables with
complete information that could be used for multiple imputation
were age at diagnosis, year of diagnosis, breast cancer detection
mode (screen-detected or not), cancer morphology (lobular/notlobular) and survival; grading data were also available but
incomplete. A fully conditional speciﬁcation (FCS) method was
applied, assuming the existence of a joint distribution for these
variables. The missing values for the variables grading, T stage, and
N stage were ﬁlled in using a discriminant function method [16]. In
the FCS method, the missing values for all variables are ﬁlled in
sequentially over the variables taken one at a time. In our setting,
grading was imputed ﬁrst conditional on the set of complete
variables, followed by T stage and then N stage. The missing values
were imputed in ﬁve runs. To assess the efﬁciency of multiple
imputation, a simulation study was carried out [17]. In 100 samples
drawn from among all women with complete UICC stage
(n = 12,437), each encompassing a sampling fraction of 20%, the
information on T and N stage was omitted and then ﬁlled up using
FCS multiple imputations. To decide whether the imputed data
delivered a good representation of the original data, we used
Box plots and tests of equivalence. The true rates of advanced
breast cancers agreed closely with those after imputation.
Age- and stage-speciﬁc breast cancer rates, including imputed
values, were computed for each calendar year from 2000 to 2013.
Overall and stage-speciﬁc incidence rates were age-standardized
using the new European standard population [18].
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In order to model the time trends we employed a log linear
Poisson model for breast cancer rates [19], stratiﬁed for stage (low
and advanced) and 5-year age group. The study intervals
comprised the pre-screening period (2000–2005), the implemen-
tation phase (2006–2008), and the subsequent period (2009–
2013) with a fully implemented screening program. Therefore, we
modeled the logarithmic annual rates with three continuous
piecewise linear functions of time according to the aforemen-
tioned time intervals. The procedure was applied for each of the
ﬁve imputation runs. The results were summarized using SAS
PROC MIANALYZE. The resulting linear splines [20] are presented
in Fig. 3. The slope parameters and the rate differences between
the beginning and end of the study period (200/2013) are displayed
in Table 2.
Statistical analyses were performed with SAS for Windows
Version 9.4 (SAS Inc., Cary, NC, USA).
3. Results
3.1. Baseline description
From 2000 to 2013, overall 13,874 cases of invasive breast
cancers were detected in the target population of women aged 50–
69 years in the Münster district. The baseline characteristics of
these women are listed in Table 1. Complete information on early
(UICC I) and advanced (UICC II+) cancers were available for
12,437 patients (89.6%).
3.2. Temporal trends of age-standardized breast cancer incidence rates
The age-standardized incidence rate of invasive breast cancer
increased markedly after the implementation of the MSP in
2005 and peaked in the year 2008 (Fig. 1). Fig. 1 also displays the
proportions of missing UICC values per calendar year.
Fig. 2 shows the age-standardized incidence rates – separately
for early- and advanced-stage breast cancer – in the MSP target
population. Clearly, the incidence rates of cancers in stage UICC ITable 2
(A) Time trends for (logarithmic) incidence rates of stage I breast cancer (BC) by periods b
implemented (2009–2013) mammography screening program (MSP). Parameter estimat
5 years age group.
Stage Age Slope 2000–
2005
[95% CI] Slope 2006–
2008
[95% CI] 
I 45–49 0.003989 [0.05711;0.04913] 0.07532 [0.00219;0.14844
I 50–54 0.066774 [0.01026;0.12329] 0.11618 [0.04841;0.18395
I 55–59 0.029229 [0.02568;0.08414] 0.18346 [0.11640;0.25052
I 60–64 0.045263 [0.00023;0.09076] 0.15557 [0.09472;0.21643
I 65–69 0.076466 [0.02804;0.12489] 0.16569 [0.10814;0.22324
I 70–74 0.070497 [0.01632;0.12467] 0.04712 [0.02828;0.122
I 75–79 0.036094 [0.03704;0.10923] 0.00896 [0.10436;0.086
(B) Time trends for (logarithmic) incidence rates of stage II+ breast cancer (BC) by period
fully implemented (2009–2013) mammography screening program (MSP). Parameter
models, per 5 years age group.
Stage Age Slope
2000–2005
[95% CI] Slope
2006–2008
[95% CI] 
II+ 45–49 0.002042 [0.04219;0.04627] 0.01508 [0.04717;0.07734
II+ 50–54 0.018466 [0.06333;0.02640] 0.00319 [0.06013;0.06651
II+ 55–59 0.014404 [0.05627;0.02747] 0.00082 [0.06137;0.05972
II+ 60–64 0.001920 [0.03803;0.03419] 0.05806 [0.00281;0.11332] 
II+ 65–69 0.011773 [0.02554;0.04908] 0.06199 [0.00981;0.11416] 
II+ 70–74 0.035916 [0.00141;0.07324] 0.00418 [0.05858;0.05022
II+ 75–79 0.009083 [0.04929;0.03113] 0.00505 [0.05265;0.06275increased after introduction of the MSP in 2005 and leveled off
after 2008, remaining elevated until 2013 as compared to the pre-
screen period. By contrast, a rise in incidence rates of advanced-
stage cancers (UICC II+) during the step-up introduction of the
program was followed by a rather consistent decline in the
incidence rates after 2008, reaching levels in 2012/13 that were
lower than in the 5 years of the pre-screening period.
3.3. Temporal trends of age-speciﬁc breast cancer incidence rates
Age-stratiﬁed analyses in 5-year age groups, involving also the
ages adjacent to the range of screening eligibility (i.e., 45–49, 70–
74 and 75–79 years), showed that the incidence rates of early-
stage cancers (UICC I) increased almost instantly after the
introduction of the MSP in the region (Fig. 3). Table 2A shows
that this rise was particularly marked in the screening of eligible
age groups as indicated by statistically signiﬁcant positive slopes.
After full implementation of the screening program, the slopes
declined again but remained elevated above the pre-screen levels.
This pattern was observed in all eligible age groups, from age
groups 50–54 years up to 65–69 years. Only a minor rise up to
2008 and a subsequent drop in incidence rates were seen in
women aged 70–74 years, and none were observed among
women of older ages. The UICC I rates for women aged 45–
49 years showed a weaker but signiﬁcant rise in parallel with the
MSP introduction. By contrast, the incidence rates of advanced-
stage breast cancers (UICC II+) remained unchanged in this and in
the youngest eligible age group (50–54 years). However, in
women aged 54–69 years, the implementation of the MSP was
accompanied by short-term increases in UICC II+ incidence which
was followed by marked declines which were statistically
signiﬁcant (Fig. 3 and Table 2B). Of note: the incidence rates of
UICC II+ cancers in women aged 55–69 years decreased to levels
that were signiﬁcantly lower than in the pre-screening period
(see difference 2000–2013 in Table 2B). Declining trends were
also observed between 2006 and 2013 in women aged 70–
74 years (Table 2B), although these did not reach statistical
signiﬁcance. In addition, the incidence level in 2013 was not lowerefore (2000–2005), during the step-up introduction (2006–2008) and with the fully
es and 95% conﬁdence intervals presented are from Poisson regression models, per
Slope 2009–
2013
[95% CI] Difference
2000–2013
[95% CI]
] 0.03547 [0.08141;0.01046] 0.02864 [0.20266;0.25993]
] 0.01356 [0.02459;0.05170] 0.75020 [0.52521;0.97519]
] 0.04523 [0.08279;
0.00768]
0.47036 [0.25426;0.68646]
] 0.00198 [0.03376;0.03772] 0.70295 [0.51459;0.89132]
] 0.02042 [0.05661;0.01576] 0.77728 [0.56346;0.99109]
52] 0.05501 [0.10425;0.00577] 0.21878 [0.03169;0.46926]
44] 0.03120 [0.02543;0.08782] 0.30957 [0.01945;0.59969]
s before (2000–2005), during the step-up introduction (2006–2008) and with the
 estimates and 95% conﬁdence intervals presented are from Poisson regression
Slope 20
09–2013
[95% CI] Difference
2000–2013
[95% CI]
] 0.00526 [0.04503;0.03452] 0.02916 [0.16532;0.22363]
] 0.01610 [0.02385;0.05606] 0.00223 [0.19149;0.18702]
] 0.05435 [0.09499;-0.01370] 0.34623 [0.53288;-0.15957]
0.08881 [0.12770;-0.04992] 0.27946 [0.45371;-0.10521]
0.11307 [0.15319;-0.07294] 0.32051 [0.51523;-0.12580]
] 0.02428 [0.06019;0.01163] 0.04562 [0.12509;0.21633]
] 0.03946 [0.00401;0.07491] 0.16706 [0.00044;0.33455]
Fig. 1. Age-standardized incidence rates of invasive breast cancer (per 100.000) from 2000 to 2013, women aged 50–69 years residing in the Münster District. The numbers
indicate the proportion of missing tumor stage information per calendar year. The two vertical reference lines indicate the start of implementation of the MSP in 2005, and full
implementation of the MSP in 2008.
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trends were observed above age 75 years.
4. Discussion
The current study investigated whether the implementation of
the MSP since 2005 affected the incidence rates of advanced-stage
breast cancers (UICC II+) in 50–69-year-old women of the Münster
district. The timing of this analysis corresponds to the pre-deﬁned
evaluation phases of the German MSP [21].
4.1. Temporal trends of early and advanced breast cancer incidence
rates
Age-standardized and age-speciﬁc analyses showed that the
incidence rates of advanced-stage breast cancer, after an initial rise
following the introduction of the MSP, started to decline after
2008 and reached levels below the pre-screening period in 2013.
Concomitantly, the incidence of early-stage (UICC I) breast cancers
increased from 2005 and have remained elevated since. This
suggests that the implementation of the MSP in the Münster
district resulted in a consistent stage shift for breast cancer in the
target population.
Esserman et al. have described a hypothetical screening
scenario where the incidence rates of early-stage cancers increase
after the introduction of a screening program, while the incidence
rates of advanced cancers decrease after a while and remainpersistently lowered [22]. In fact, we observed a short rise in the
rates of advanced breast cancers after the introduction of the MSP;
we suggest that this was attributable mainly to the increased
detection of clinically asymptomatic N+ tumors in the prevalence
round of the screening. The subsequent decline of advanced breast
cancer incidence rates is considered one of the best indicators of an
effective MSP [23–25]. Declines following the introduction of an
MSP have been consistently reported in those randomized clinical
trials that achieved marked mortality reductions; this led Tabar
et al. to suggest that breast cancer mortality reductions can be
expected only in settings that are effective in reducing advanced-
stage breast cancers [25].
4.2. Declines in advanced breast cancer incidence rates and
mammography screening
Our study revealed marked and statistically signiﬁcant declines
in advanced breast cancer rates, mainly in women aged 55–
69 years. By contrast, many countries with long-standing
mammography screening programs have not seen clear declines
in incidence rates of advanced breast cancer. A systematic review
by Autier et al. concluded that in many population studies in
Europe, North America and Australia, only small declines, if any at
all, were observed [11,23]. Interestingly, while a much-cited recent
study from the US reported only marginally reduced rates of
advanced-stage cancers [12], another study, adjusting for the
temporal trends before screening program initiation, found a
Fig. 2. Age-standardized incidence rates (per 100.000) of early (stage I) and advanced (stage II+) invasive breast cancer from 2000 to 2013, women aged 50–69 years residing
in the Münster District. Cases with missing data on tumor staging were imputed. The two vertical reference lines indicate the start of implementation of the MSP in 2005, and
full implementation of the MSP in 2008.
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population [9]. In the Netherlands, a study by a team of radiologists
observed that rates of advanced breast cancers in women with
screen-detected and interval cancers remained constant over time
[14]. Likewise, reviewing the Norwegian MSP, Lousdal et al. found
no decline in the incidence of late-stage cancers in the screening
target group of 50–69-year-old women compared to an un-
screened group of 20–49-year-old women [13]. On the other hand,
several studies observed declining incidence rates of advanced
breast cancers after the introduction of organized mammography
screening. For example, declining rates of advanced-stage breast
cancers were found early in the Dutch MSP [7], and signiﬁcantly
lower incidence rates for stage III and IV cancers were also reported
from two studies in Norway [13,26]. A recent study described that
the incidence of advanced breast cancer would have been 29%
higher without mammography screening when employing an age–
period–cohort model based on US SEER (Surveillance, Epidemiol-
ogy, and End Results Program) data [8]. In Italy, a signiﬁcant decline
in advanced (pT2 to pT4) breast cancer cases occurred from year
3 onwards after the implementation of the MSP in over
700 municipalities of six administrative regions [6].
4.3. Validity aspects of the study ﬁndings
These controversial study ﬁndings are often related to differ-
ences in the methodology used, as described previously [23,27]. In
particular, there is no concurrent control group when an organizedscreening program is offered to the entire population, as was the
case in Germany. Therefore, the present results must ﬁrst be
viewed as a mere description of the trend of advanced breast
cancer incidence after the implementation of the MSP in the
Münster district, that is, as an ecological study. The evidence level
of this type of epidemiological observational study is low and
cannot ﬁrmly establish causal relations. However, arguments of
consistency and plausibility of the ﬁndings may help to enforce the
credibility of a causal interpretation. First, changes for both early
and advanced breast cancer incidence occurred strictly after the
introduction of the MSP, plausibly corroborating a temporal
sequence. Second, these changes were mostly conﬁned to the
age groups that were also eligible for MSP; they were not seen in
younger or older age groups. Third, while rises in early-stage breast
cancer incidence rates after 2005 were seen in all eligible age
groups (50–69 years), decrement of advanced breast cancers was
observed in those aged 55–69 years; this was indeed to be
expected because lead time results in advancement of early-stage
breast cancer detection to younger age groups while causing at the
same time the incidence of advanced stages to decrease in the
older age groups. In fact, even the weaker declines in the age group
70–74 years may be potentially attributable to a ‘spill-over effect’
of decreasing advanced-stage incidence rates due to this detection
advancement. Of note, it is understood that a potential concurrent
decline in the ‘natural’ incidence of advanced-stage breast cancers
without a screening program cannot be completely ruled out by
these arguments; however, in our view, the ﬁndings in this study
Figure 3. Incidence rates for early (stage I) and advanced (stage II+) breast cancer among women aged 45–79 years in the Münster District, between 2000 and 2013, by 5 years
age group (data points). The black lines represent period speciﬁc estimates of trends in incidence rates as obtained from Poisson regression models; the blue shaded areas
represent the respective 95% conﬁdence bands. The two vertical dotted lines demarcate the transition from the pre-screen period (2000–2005) to the step-up introduction
phase of the mammography screening program (2006–2008), and between the step-up introduction and the subsequent phase of full implementation (2009–2013). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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impact of the MSP on the incidence of advanced-stage breast
cancer in the target population. On the other hand, the
participation rate per screening round was only about 55%
between 2006 and 2012 in this MSP, and this may appear too
low to create such a marked population impact. However, in the
population perspective, the cumulative proportion of ‘ever
screened’ women, that is, of women who have participated in
the MSP at least once in the entire period, was higher and ranged at
about 70% due to women who responded to the invitation only in
the second or third screening rounds. We also considered that
opportunistic mammography screening was widespread before
the introduction of the organized MSP [28] and that this may have
contributed to the observed declines. However, data provided bythe statutory health insurances in NRW reveal that opportunistic
screening dropped substantially and persistently in the wake of
MSP implementation. Hence, previous opportunistic screening
does not seem to be able to plausibly explain why declines in
advanced stages of incident breast cancers occurred after an initial
increase from around 2005 and a decline mostly after 2008. Finally,
the initial increase in advanced-stage cancers after the start of the
MSP may be in part attributable to stage migration due to the
increased use of sentinel lymph-node biopsies (SNBs). The
Association of German Tumor Centers reported an increase in
SNBs from about 30% in 2005 to 80% in 2011 [29], which may have
resulted in some upstaging of breast cancers. However, the large
majority of lymph-node involvements detected by SNB are due to
micrometastases [30,31] which will not have accrued as advanced
50 A. Simbrich et al. / Cancer Epidemiology 44 (2016) 44–51stages (UICC II+) but as UICC IB. Moreover, the permanent
upstaging of breast cancers cannot explain the decline in
UICC II+ cancers after 2008 because stage-shift should have
mitigated rather than ampliﬁed the observed decline.
4.4. Strengths and limitations
A key strength of this study is the longstanding, large and
population-based study sample of women with breast cancer that
was assembled with a high level of completeness (>90%) in a well-
deﬁned study area. This enabled the thorough investigation of the
temporal trends of breast cancer incidence rates in the target
population before and after the start the MSP. Of note, a certain
degree of incomplete cancer registration was observed in the year
2004, resulting from a restructuring of the registration process and
the transformation to a system of statewide cancer registration in
2005. We employed Poisson regression modeling to attenuate the
variability between calendar years such that the relative ‘reporting
gap’ in 2004 presumably had only a minor inﬂuence on our results.
Furthermore, decreased use of postmenopausal hormone
therapy (PMH) has been shown in the past to inﬂuence total
breast cancer incidence rates [32,33]. Unfortunately, to date there
are no studies showing a differential impact of the falling PMH use
on early- and late-stage breast cancer incidence; thus, a potential
role of different patterns of PMH therapy in the observed incidence
trends cannot be completely ruled out.
Finally, the study population is not necessarily representative
for all eligible women in Germany, and the ﬁndings apply strictly
only to the Münster district; on the other hand, the systematic
screening procedures, including standardized indicators of process
quality, are by and large comparable for all German regions. Thus,
we suggest that our ﬁndings may be assumed to also possess a
relevant level of external validity.
5. Conclusions
We provide a description of trends in advanced breast cancer
incidence rates in the female population before and after the
implementation of the MSP in the Münster district. Our data show
that the fully implemented program was associated with a
decrease in the incidence rates of advanced breast cancers after
a step-up introduction period. By contrast, early-stage breast
cancer incidence rates increased almost instantaneously after
starting the program. Age-speciﬁc analyses suggest that the
decline in unfavorable breast cancer stages in older age groups
is due to advancing early-stage breast cancer detection in younger
age groups.
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